Introduction {#S1}
============

Iron cofactors are required for the activity of hundreds of proteins that perform critical functions within cells. The simplest cofactors are mononuclear or dinuclear iron centers directly coordinated within the active sites of enzymes or regulatory proteins found throughout the cell. The more complex cofactors, heme and iron--sulfur (Fe--S) clusters, are synthesized by dedicated cellular machines. The final step of heme synthesis occurs exclusively within mitochondria, while heme proteins are located in every subcellular compartment^[@R1]^. Fe--S clusters are assembled and repaired in both the mitochondria and cytosol, while Fe--S cluster proteins are additionally located in the nucleus^[@R2],[@R3]^. Each of these cofactors requires compartment-specific distribution systems that protect the cofactors from chemical attack, facilitate their insertion into target proteins, and prevent their adventitious binding in non-target sites. Cofactor assembly and distribution systems have been studied, but substantial gaps in our knowledge of these systems persist.

In the cytosol of mammalian cells, delivery of Fe(II) ions to mono- and di-iron enzymes is facilitated by the poly r(C)-binding protein (PCBP) family^[@R4],[@R5]^. PCBPs are adaptor proteins that bind multiple types of ligands, affecting their fates^[@R6]--[@R10]^. PCBP1 and PCBP2 bind to C-rich motifs in many types of RNAs and single stranded DNAs and can alter their processing. Structurally, PCBPs contain three conserved RNA-binding domains, termed heterogeneous nuclear ribonucleoprotein K-homology (KH) domains, which have specific roles in interactions with RNA and proteins. PCBP1 and PCBP2 also function as iron chaperones in the cytosolic/nuclear compartment^[@R11]^. *In vitro* studies demonstrate that PCBP1 can bind 3 ferrous ions with affinities in the low micromolar range, similar to the levels of kinetically exchangeable iron in the cytosol^[@R12]^. The molecular details of how PCBPs coordinate labile iron have not been determined. PCBP1 and, to a lesser extent, PCBP2 deliver ferrous iron to ferritin, an iron storage protein, and to specific, cytosolic iron enzymes^[@R13]^. These targets include the prolyl hydroxylases, which regulate hypoxia-inducible factor 1α, and deoxyhypusine hydroxylase, which hypusinates EIF5A^[@R14],[@R15]^. Mice lacking PCBP1 in bone marrow exhibit anemia and defects in red blood cell heme synthesis due to impaired flux of iron through ferritin^[@R16]^. PCBP2 can specifically interact with membrane proteins, facilitating iron import through DMT1^[@R17]^ and export through ferroportin^[@R18]^. PCBP2 may also capture iron released from heme oxygenase 1 and 2^[@R19]^. HEK293 cells depleted of PCBP1 or PCBP2 exhibit low activity of cytosolic aconitase^[@R14]^, a labile \[4Fe--4S\] cluster enzyme. This suggests that PCBP1 or PCBP2 may also be directly or indirectly involved in synthesis or repair of Fe--S clusters.

Iron--sulfur cluster assembly occurs in the cytosol via a system distinct from that of the mitochondria^[@R20],[@R21]^; numerous proteins required for the maturation and distribution of \[4Fe--4S\] clusters to cytosolic and nuclear enzymes have been identified^[@R2],[@R3]^. However, the early steps that result in the assembly of a \[4Fe--4S\] cluster have remained murky. In yeast, the initial steps of \[2Fe--2S\] cluster assembly occur on core machinery located in the mitochondria; some product of this machinery is exported to the cytosol for cytosolic Fe--S assembly^[@R20]^. Mammalian cells exhibit dual localization of core components to both mitochondria and cytosol, which may facilitate *de novo* Fe--S assembly in the cytosol^[@R22]^. The earliest steps in cytosolic Fe--S cluster assembly require the incorporation of an inorganic sulfur species generated by cysteine desulfurase. This species is exported from mitochondria via the transporter ABCB7, although the chemical nature of this sulfur-containing species has not been defined and may be produced in the cytosol, as well^[@R23]^. Similarly, the source of iron for cytosolic Fe--S assembly has not been identified. The scaffolds upon which the simplest clusters, \[2Fe--2S\], are assembled likely involve cytosolic isoforms of the core Fe--S machinery. Another candidate scaffold for assembly of cytosolic Fe--S clusters involves the cytosolic monothiol glutaredoxin, Glrx3. Yeast cells lacking Glrx3 homologues exhibit severe defects in cytosolic \[4Fe--4S\] assembly, while depletion of Glrx3 in fish and human cells leads to more subtle defects in Fe--S assembly and iron homeostasis^[@R24]--[@R26]^. Recent evidence indicates that Glrx3 functions as a \[2Fe--2S\] cluster chaperone in human cells and requires the cytosolic BolA-like protein, BolA2, to coordinate \[2Fe--2S\] clusters and transfer them to an early-acting component of the cytosolic Fe--S assembly machinery^[@R27]^.

Here we have used affinity-capture and mass spectrometry to identify proteins that associate with PCBP1 in human cells. We identify BolA2 in complex with PCBP1 and demonstrate that PCBP1--BolA2 forms a distinct iron chaperone complex for cytosolic \[2Fe--2S\] cluster assembly.

Results {#S2}
=======

BolA2 forms a complex with PCBP1 without Glrx3 {#S3}
----------------------------------------------

To determine the proteins interacting with PCBP1 in mammalian cells, we performed proteomic analysis on complexes isolated from HEK293 cells expressing an inducible, N-terminal Flag-tagged PCBP1. Affinity purification followed by mass spectrometry analysis of Flag-PCBP1 complexes revealed more than 200 interacting proteins, including RNA-binding proteins, ferritin, and some novel targets^[@R28]^. PCBP1 was associated with the cytosolic BolA-like protein, BolA2 ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Iron supplementation of cells enhanced the PCBP1--BolA2 interaction, while high salt washes dissociated the PCBP1--BolA2 complex. Although Glrx3 is found in complex with BolA2 in HEK293 cells, Glrx3 was not found in immunoprecipitates of PCBP1. This association between PCBP1 and BolA2 was confirmed by reciprocal co-immunoprecipitation (co-IP) analysis using ectopically expressed proteins in HEK293 cells. IP using anti-Flag resin followed by Western blotting with anti-BolA2 antiserum revealed that BolA2 was readily detectable in immune complexes from cells expressing PCBP1-Flag, but not from cells containing an empty vector, confirming the specificity of the interaction ([Fig. 1a](#F1){ref-type="fig"}). Similarly, PCBP1 was identified in complexes from cells expressing BolA2-Flag but was undetectable in cells containing empty vector ([Fig. 1b](#F1){ref-type="fig"}). We constructed inducible cell lines that expressed BolA2-Flag at levels similar to endogenous BolA2. PCBP1 was readily detected in immune complexes from this cell line, whether PCBP1 was expressed at the endogenous level or overexpressed ([Fig. 1c](#F1){ref-type="fig"}). Thus, these results confirm that PCBP1--BolA2 complexes form in mammalian cells. In contrast, similar experiments designed to detect PCBP2 in complex with BolA2 did not reproducibly demonstrate PCBP2 in precipitates of BolA2-Flag ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}), indicating that the BolA2 complex was specific to PCBP1.

In human cells, BolA2 complexes with the cytosolic monothiol glutaredoxin, Glrx3^[@R27]^. To investigate whether Glrx3 was involved in PCBP1--BolA2 formation, we performed co-IP in cells depleted of Glrx3 using small interfering RNA (siRNA). BolA2-Flag complexes from cells depleted of Glrx3 contained 3-fold higher levels of PCBP1--BolA2 compared to cells treated with control siRNA ([Fig. 1d](#F1){ref-type="fig"}). In contrast, cells overexpressing *myc*-tagged Glrx3 contained 60% lower levels of PCBP1--BolA2 compared to controls ([Fig. 1e](#F1){ref-type="fig"}), suggesting that Glrx3 competes with PCBP1 for BolA2 binding. These results demonstrate that PCBP1 and BolA2 form a complex independent of Glrx3 and interaction between PCBP1 and BolA2 is enhanced in the absence of Glrx3.

BolA2 requires PCBP1 to bind iron without Glrx3 {#S4}
-----------------------------------------------

In human cells, the BolA2--\[2Fe--2S\]--Glrx3 chaperone complex serves as a rapidly expandable pool of Fe--S clusters and responds to changes in cellular iron status^[@R27]^. However, BolA2 has not been reported to bind iron independently. To directly measure the amount of iron associated with BolA2, we induced BolA2-Flag expression, labelled cells with ^55^FeCl~3,~ and measured the amount of ^55^Fe co-precipitating with BolA2-Flag ([Fig. 2a](#F2){ref-type="fig"}). We detected ^55^Fe in BolA2-Flag complexes at levels 5-fold greater than uninduced control cells, indicating that we could measure the ^55^Fe associated with BolA2. To test whether Glrx3 was required for iron binding to BolA2, we depleted Glrx3 and found the amount of ^55^Fe bound to BolA2-Flag was only modestly diminished (\< 20% reduction) compared to Glrx3-expressing cells ([Fig. 2b](#F2){ref-type="fig"}). To test whether PCBP1 was required for iron binding to BolA2, we measured the amount of ^55^Fe co-precipitated with BolA2-Flag from PCBP1-depleted or PCBP1-overexpressing cells under Glrx3-depleted conditions. The amount of ^55^Fe associated with BolA2-Flag was markedly reduced (\>80% reduction) in cells co-depleted of PCBP1 and Glrx3 ([Fig. 2c](#F2){ref-type="fig"}). In contrast, when PCBP1 was overexpressed in the absence of Glrx3, we measured a 300% increase in ^55^Fe bound to BolA2-Flag. These results suggested that iron binding to BolA2 largely depends on PCBP1 and does not require Glrx3.

PCBP1--BolA2 requires iron and glutathione for stability {#S5}
--------------------------------------------------------

In human cells, BolA2--Glrx3 complex formation depends on the incorporation of \[2Fe--2S\] clusters^[@R27]^. BolA2 forms a \[2Fe--2S\]-bridged heterotrimeric complex with Glrx3, with iron ions coordinated by a conserved cysteine and histidine from BolA2, a cysteine from Glrx3, and the cysteine moiety of noncovalently bound, reduced glutathione (GSH) on Glrx3^[@R25],[@R29]^. GSH is an abundant tripeptide, attaining concentrations of 2--10 mM in mammalian cells, and serves as the primary intracellular thiol redox buffer and cofactor for glutaredoxins and other antioxidant enzymes^[@R30]^. To understand complex formation between PCBP1 and BolA2, we overexpressed PCBP1 and BolA2-Flag and performed co-IP in the presence or absence of GSH and/or iron. PCBP1--BolA2 was stable to immunoprecipitation when isolated in buffer containing 5 mM GSH ([Fig. 3a](#F3){ref-type="fig"}). In contrast, addition of iron chelators and/or omission of GSH destabilized the complex, resulting in a 70% decrease in PCBP1--BolA2. Moreover, addition of an alternative reducing agent, dithiothreitol, did not result in stabilization of PCBP1--BolA2 complexes ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). These data suggest that both iron and GSH are required for stable PCBP1--BolA2 complex formation.

We next determined whether inorganic sulfur was required for the PCBP1--BolA2 interaction. Nfs1 encodes the sole cysteine desulfurase in mammalian cells; cells lacking this enzyme are unable to produce sulfide for both mitochondrial and cytosolic Fe--S cluster synthesis^[@R31]^. Using siRNA, we depleted Nfs1 and/or Glrx3 in the inducible BolA2-Flag cell line, labelled cells with ^55^FeCl~3~ and measured the amount of ^55^Fe and PCBP1 co-precipitating with BolA2-Flag ([Fig. 3b](#F3){ref-type="fig"}). The amounts of ^55^Fe co-precipitated with BolA2-Flag were similar in control-, Glrx3-, and Nfs1/Glrx3-depleted cells. Furthermore, the cells depleted of Nfs1 and Glrx3 contained similar levels of PCBP1--BolA2 as control cells, suggesting that inorganic sulfide or an Fe--S cluster was not required for iron binding to BolA2 or for PCBP1--BolA2 complex formation.

Because Glrx3 appears to compete with PCBP1 for binding and iron coordination with BolA2, we questioned whether the same site on BolA2 was involved in the formation of both complexes. Conserved Cys31 and His68 in human BolA2 are required for Fe--S cluster coordination with Glrx3^[@R29]^. Both PCBP1 and Glrx3 were readily detectable in anti-Flag IPs from cells expressing wild type BolA2-Flag compared to an empty vector negative control ([Fig. 3c](#F3){ref-type="fig"}). In BolA2-Flag mutants C31S and H68A, levels of co-precipitating Glrx3 and PCBP1 were reduced to 25% and 5% of wild type levels, respectively. These results suggest that the same iron-binding residues on BolA2 are necessary for the formation of the BolA2--Fe--PCBP1 as well as the BolA2--\[2Fe--2S\]--Glrx3 complex.

PCBP1 delivers iron to the BolA2--\[2Fe--2S\]--Glrx3 complex {#S6}
------------------------------------------------------------

Whether PCBP1 requires GSH or a protein partner such as BolA2 for iron coordination in cells remains to be determined. We transfected cells with plasmids encoding PCBP1-Flag and BolA2 or a control plasmid, labeled cells with ^55^FeCl~3~, and measured the amount of iron and BolA2 co-precipitating with PCBP1 ([Fig. 4a](#F4){ref-type="fig"}). The amount of BolA2 co-precipitating with PCBP1 mirrored the overall level of BolA2 expression: cells overexpressing BolA2 exhibited abundant BolA2--PCBP1, while cells expressing low levels of BolA2 exhibited very low amounts of the complex. In contrast, similar amounts of ^55^Fe were associated with PCBP1-Flag from cells overexpressing BolA2 or not, suggesting that PCBP1 binds iron independently of BolA2. To determine the effect of GSH on iron binding to PCBP1, we measured the amount of ^55^Fe associated with PCBP1 when BolA2 was low and GSH was omitted from the lysis buffer. In the absence of GSH, the ^55^Fe bound to PCBP1 fell to 10% of the level present when buffer contained GSH ([Fig. 4a](#F4){ref-type="fig"}). Collectively our data indicated that PCBP1 requires GSH, but not BolA2, to bind iron.

Unlike *in vitro* studies^[@R32]^ or in yeast cells^[@R33]^, in human cells, formation of a BolA2--Glrx3 complex requires the coordination of \[2Fe--2S\] clusters; in the absence of Fe--S clusters, BolA2 and Glrx3 do not form a stable complex^[@R27]^. Because PCBP1 is involved in the distribution of ferrous iron in the cytosol of mammalian cells^[@R11],[@R14],[@R15]^, we tested whether the iron chaperone activity of PCBP1 was required to form BolA2--\[2Fe--2S\]--Glrx3 complexes. Cells expressing or depleted of PCBP1 or the homologous PCBP2 were examined for BolA2--\[2Fe--2S\]--Glrx3 formation ([Fig. 4b](#F4){ref-type="fig"}). Isolated BolA2-Flag immune complexes from cells lacking PCBP1 contained less than 30% of the Glrx3 found in control cells expressing PCBP1, indicating that PCBP1 is required for the formation of the \[2Fe--2S\] clusters needed to form the BolA2--\[2Fe--2S\]--Glrx3 complex and that endogenous PCBP2 cannot substitute for PCBP1. Surprisingly, cells lacking PCBP2 exhibited enhanced BolA2--\[2Fe--2S\]--Glrx3 complex formation. Co-depletion of both PCBP1 and PCBP2 resulted in impaired complex formation, indicating that PCBP1 is required for the enhanced complex formation seen in PCBP2-depleted cells. Overall, these data suggest that PCBP1 has a specific role in providing iron for the formation of the BolA2--\[2Fe--2S\]--Glrx3 complex. PCBP2 may impact this process by competing with PCBP1 for cytosolic iron.

Previous work shows that the loss of iron chaperone activity associated with PCBP1 depletion can be rescued by supplementing cells with excess iron at levels sufficient to raise the cytosolic pool of iron ^[@R14],[@R15]^. We tested the effects of iron supplementation on BolA2--Glrx3 formation and found that again, BolA2--\[2Fe--2S\]--Glrx3 complex formation was enhanced in control cells; furthermore, complex formation in cells lacking PCBP1 could be restored by iron supplementation, indicating that the iron chaperone activity of PCBP1 promoted \[2Fe--2S\] cluster formation on Glrx3 and BolA2 ([Fig. 4c](#F4){ref-type="fig"}).

KH3 domain promotes \[2Fe--2S\] formation on BolA2--Glrx3 {#S7}
---------------------------------------------------------

Structurally, PCBPs contain three KH domains: KH1 and KH2 in the amino terminus and KH3 in the carboxyl terminus, which are separated by an unstructured variable domain. We mapped the domain(s) of PCBP1 involved in interactions with BolA2. PCBP1 variants containing individual Flag-tagged domains were expressed in cells and examined for their capacity to co-precipitate BolA2 ([Fig. 5a](#F5){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Interestingly, both the KH1 and KH3 domains co-precipitated BolA2 at levels similar to the full-length PCBP1, while the KH2 domain exhibited no interaction. Co-precipitation of BolA2 with the KH1 or KH3 domain was lost in the absence of GSH or iron, as was observed earlier with full-length PCBP1 ([Fig. 3a](#F3){ref-type="fig"}). Thus, iron- and GSH-dependent BolA2 binding occurs with both the KH1 and KH3 domains of PCBP1.

We next determined whether a single KH domain could substitute for the full-length PCBP1 in facilitating BolA2--\[2Fe--2S\]--Glrx3 complex formation. We depleted endogenous PCBP1, expressed siRNA-resistant PCBP1 or KH-Flag domains, then measured the amount of Glrx3 co-precipitating with BolA2-Flag. As observed in [Figure 4b](#F4){ref-type="fig"}, the BolA2--Glrx3 complex was destabilized upon depletion of endogenous PCBP1 ([Fig. 5b](#F5){ref-type="fig"}) and overexpression of full-length PCBP1 restored the BolA2--Glrx3 complex to non-targeting control levels. In contrast, neither KH1 nor KH2 domains restored the BolA2--Glrx3 complex in the absence of PCBP1, despite the capacity of KH1 to bind to BolA2. Instead, KH3 overexpression was sufficient to restore BolA2--Glrx3 complex formation to the level of full-length PCBP1. These data indicated that the carboxyl-terminal KH3 domain of PCBP1 was functionally sufficient to promote formation of the BolA2--\[2Fe--2S\]--Glrx3 complex in cells lacking endogenous PCBP1.

We then conducted a structure-function analysis of the BolA2--KH3 complex using site-directed mutagenesis of the KH3 domain. After examining the crystal structure of KH3, we engineered substitution mutations in (i) a conserved cysteine (Cys293) reported to undergo iron-dependent homocysteinylation^[@R34]^, (ii) residues identified by modeling GSH binding on KH3, (iii) residues in the vicinity of Cys293 that could serve as N-, O-, and S-based Fe(II) ligands^[@R35]^, and (iv) residues coordinating RNA in the structure of a KH3--RNA complex^[@R36]^. Wild-type and mutant versions of KH3 were expressed in cells and examined for their capacity to co-precipitate BolA2 ([Fig. 5c](#F5){ref-type="fig"},[d](#F5){ref-type="fig"} and [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). KH3 mutants carrying substitutions in residues coordinating RNA (Gly296, Arg297, Gly299, Arg306, Arg325) demonstrated BolA2 binding at levels similar to wild-type KH3, suggesting that the binding site for BolA2 was distinct from the RNA-binding site. In contrast, KH3 mutants C293S, N301A, E304S, R346A, E350A, N301A/R346A bound BolA2 at levels 5--30% of wild-type KH3. We further analyzed the ^55^Fe binding activity of these KH3 mutants and found that all of the amino acid substitutions that impaired BolA2 binding also reduced iron coordination to levels 10--30% of wild-type KH3 ([Fig. 5c](#F5){ref-type="fig"}). To directly assess residues potentially involved in GSH binding, KH3 IPs were labeled *in vitro* with ^35^S-GSH. Wild-type KH3 bound GSH at 5-fold greater levels than control IPs, indicating that isolated KH3 can directly bind GSH. All of the KH3 mutants predicted to affect GSH coordination (Asn301, Glu304, Arg346) exhibited reduced levels (\< 30% of wild-type) of ^35^S-GSH-binding. In contrast, predicted iron-binding mutants C293S and E350A exhibited no defect in GSH binding. Mutation of non-conserved Cys355 did not affect BolA2 coordination ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}), suggesting the iron-binding function of Cys293 was specific and not a general feature of sulhydryl residues on KH3. Together these data suggested that KH3 can directly coordinate both GSH and iron at adjacent sites on the domain and that both ligands are required for coordination of BolA2.

Finally, we determined whether the C293S mutation in full-length PCBP1 could block the formation of the BolA2--\[2Fe--2S\]--Glrx3 complex. We expressed wild-type or mutant PCBP1^C293S^ in PCBP1-depleted cells and measured the formation of the BolA2--Glrx3 complex ([Fig. 5e](#F5){ref-type="fig"}). Mutant PCBP1^C293S^ did not support complex formation, as levels of co-precipitated Glrx3 were similar to those of PCBP1-depleted control cells. Thus, the Fe--GSH binding site on the KH3 domain of PCBP1 was necessary and sufficient to facilitate formation of the BolA2--\[2Fe--2S\]--Glrx3 complex.

Allosteric binding of iron and GSH to KH3 {#S8}
-----------------------------------------

Our data obtained from cells suggested that both iron and GSH were involved in the formation of the BolA2--KH3 complex. To determine the effects of each ligand on the binding of the other, we purified recombinant KH3 and BolA2 ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}) and performed *in vitro* analyses of ligand binding. To measure the allosteric effects of Fe(II) on the binding of GSH by the PCBP1 KH3 domain, we used microscale thermophoresis of fluorescently labeled KH3 ([Fig. 6a](#F6){ref-type="fig"}). Titration of GSH in buffers without iron indicated an apparent K~D~ = 390 ± 50 μM, while titration of GSH in buffer containing 10 μM Fe(II) demonstrated a ∼5-fold higher affinity of GSH for KH3, with a K~D~ = 80 ± 10 μM. We confirmed the effect of iron on *in vitro* GSH binding by KH3 using the ^35^S-GSH assay ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). Wild-type KH3 directly bound GSH in the absence of added iron and increased GSH binding 2-fold in the presence of Fe(II), while mutant KH3^C293S^ exhibited wild-type levels of GSH binding that did not increase with addition of iron, thus supporting the allosteric activity of iron.

To precisely characterize the iron coordination by the purified KH3 domain of PCBP1, we determined its Fe(II)-binding affinities and the allosteric effects of GSH using the competitive iron-binding chromophore Mag-Fura 2 (MF2). Iron binding by MF2 was monitored spectrophotometrically^[@R37],[@R38]^ and glutathione at physiological concentrations did not interfere with Fe binding ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}). We then titrated Fe(II) into a mixture of MF2 and purified KH3 ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}), calculated the free Fe(II) and Fe--KH3/total KH3 levels, and determined the K~D~ and apparent stoichiometry for the Fe--KH3 complex ([Fig. 6b](#F6){ref-type="fig"}). Wild-type KH3 bound Fe(II) in the absence of glutathione at K~D~ = 4.2 ± 0.7 μM. GSH increased the affinity of KH3 for Fe(II) by \~5-fold, with K~D~ = 0.8 ± 0.1 μM in 5 mM GSH and a stoichiometry of 1:1. We confirmed these measurements by performing similar analyses using the chromophore Fura-4f, which exhibits a higher affinity for Fe(II) ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). The C293S KH3 variant showed significantly lower Fe(II) binding affinities, with K~D~ = 16.4 ± 2.7 μM at 0 mM GSH and K~D~ = 9.4 ± 1.3 μM at 5 mM GSH. Fe binding to the C293S variant exhibited a metal:protein stoichiometry nearer to 0.5:1, suggesting that this mutant KH3 may coordinate Fe(II) as a dimer. Thus, GSH binding can allosterically stabilize the Fe--KH3 complex. Furthermore, the affinity of Fe(II) for KH3 in presence of GSH is sufficient to promote Fe(II)--PCBP1 complex formation in the cytosol, as the concentration of chelatable iron in the cytosol has been measured in the low micromolar range (0.5--2 μM)^[@R12],[@R39],[@R40]^.

We determined whether the identified factors were sufficient to reconstitute the KH3--BolA2 complex *in vitro*. We mixed purified KH3-Flag and BolA2 in buffer with or without Fe(II) and GSH and determined the amount of BolA2 bound to KH3-Flag after capture on the anti-Flag resin ([Fig. 6c](#F6){ref-type="fig"}). The *in vitro* reconstitution closely mimicked complex formation in cells: BolA2 was co-precipitated with KH3-Flag only in the presence of Fe and GSH. Reconstitution of the KH3--BolA2 complex without any added source of sulfur supported our observation that the KH3--BolA2 complex coordinates iron, but not an iron--sulfur cluster. Similar experiments using BolA2 and KH3-Flag variant C293S failed to reconstitute the KH3--BolA2 complex, even with addition of Fe and GSH ([Fig. 6d](#F6){ref-type="fig"}), indicating that iron coordination by Cys293 of the KH3 domain was required for complex formation with BolA2. We determined the stoichiometry of the KH3--BolA2 complex using size exclusion chromatography ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). In the absence of GSH and iron, a mixture of KH3 and BolA2 migrated as monomers, at the expected molecular sizes of 15 and 12 KDa, respectively. In mixtures of BolA2 and KH3 that included GSH and iron, a complex of BolA2--KH3 was detected at the molecular size of 27 KDa, indicating formation of a 1:1 BolA2--KH3 heterodimer.

To quantitatively examine the effect of GSH on BolA2--KH3 complex formation, we performed *in vitro* reconstitution and quantitative pull-down assays across a broad range of GSH concentrations ([Fig. 6e](#F6){ref-type="fig"} and [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}). The affinity of GSH for the BolA2--KH3 complex was K~D~ = 86 ± 25 μM, which was similar to the affinity of GSH for KH3 alone in the presence of iron ([Fig. 6a](#F6){ref-type="fig"}). Because BolA2 binding did not affect the apparent affinity of GSH for the BolA2--KH3 complex, these data suggest that the GSH bound to KH3 does not directly interact with the BolA2 protein. Furthermore, these data support a model in which a molecule of GSH, noncovalently bound to KH3, contributes directly to the coordination of iron in KH3 by serving as an iron ligand, and making the KH3-bound iron sterically available for coordination with BolA2.

Finally, we determined the affinity of BolA2 for the intact, preformed KH3--Fe--GSH complex. We mixed KH3-Flag with Fe(II) and GSH, then added BolA2 in a range of concentrations ([Fig. 6f](#F6){ref-type="fig"}). The apparent dissociation constant for KH3--BolA2 complex was K~D~ = 0.9 ± 0.3 μM. Because the affinities of Fe and GSH for KH3 and KH3 for BolA2 determined in these studies are concentrations within the physiological range present in cells, the iron chaperone complexes defined in these *in vitro* studies likely represent complexes that form in cells.

Discussion {#S9}
==========

The studies presented here reveal functions of PCBP1 in complex with BolA2. Together, they form an iron chaperone complex, transferring iron in the early steps of cytosolic Fe--S cluster assembly, thus linking the cytosolic labile iron pool to the cytosolic Fe--S cluster assembly process. These studies also demonstrate that PCBP1 can bind iron in the cytosol as an Fe(II)--GSH complex. Previous *in silico* analyses of potential small-molecule ligands for iron suggested that over 95% of the kinetically exchangeable cytosolic iron pool is likely to be coordinated by the free thiol in reduced GSH^[@R41]^. Here we show that the KH3 domain (and likely the KH1 domain) of PCBP1 binds Fe and GSH with 1:1 stoichiometries and affinities that, at equilibrium, would support complex formation in the cytosol. Allosteric effects of each ligand on the binding of the other support the coordination of an Fe--GSH complex on KH3 in which the free sulfhydryl of GSH functions as an iron ligand, along with Cys293 and Glu350, to stabilize bound iron. GSH coordination appears to be necessary for the Fe(II) to coordinate the Cys31 and His68 ligands of BolA2, as the iron-bound form of KH3 without GSH did not bind BolA2 *in vitro*. *In silico* docking analysis between KH3 and BolA2 suggested a possible electrostatic protein--protein interaction wherein the putative iron-binding residues on BolA2 and KH3 are positioned at the modeled interface of the two protomers ([Supplementary Fig. 10](#SD1){ref-type="supplementary-material"})^[@R42]^. The coordination of Fe--GSH on KH3 may confer selectivity for Fe(II), as cytosolic manganese, although present in concentrations similar to Fe(II), binds GSH with \> 100-fold lower affinity than Fe(II)^[@R43]^. Thus, the coordination of Fe--GSH complexes on PCBP1 potentially accounts for its metal specificity as an iron chaperone and suggests that much of the cytosolic iron pool is in the form of PCBP1--Fe--GSH complexes.

The Cys293 residue that is critical for iron binding on KH3 was previously identified as a site that modulates the RNA binding activity of PCBP1. In folate-deficient placental cells, PCBP1 (also called hnRNP E1) is reversibly homocysteinylated on Cys293, which enhances its affinity for folate receptor mRNA and increases the expression of folate receptor^[@R34],[@R44],[@R45]^. In these studies, iron and glutathione reduces the affinity of PCBP1 for mRNA, which is likely due to the coordination of Fe--GSH. Thus the RNA-binding and iron chaperone activities of PCBP1 may be coordinately regulated in cells.

Our genetic loss-of-function studies indicate that PCBP1 is required for the formation of the \[2Fe--2S\] clusters that bridge the Glrx3--\[2Fe--2S\]--BolA2 complex. In human cells, Glrx3 and BolA2 form a complex only when they coordinate the bridging \[2Fe--2S\] clusters. Although both the KH1 and the KH3 domains of PCBP1 bound to BolA2 in an Fe- and GSH-dependent manner, only KH3 could support the formation of \[2Fe--2S\] clusters on the BolA2--Glrx3 complex in cells. Sequence comparison of KH1 and KH3 reveals that Cys293 in KH3 is not conserved in KH1, although residues that could contribute O^−^ ligands are present. Thus, the sulfhydryl from Cys293 may be specifically required to facilitate transfer of Fe(II) or Fe--GSH from PCBP1--BolA2 to BolA2--Glrx3 ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}). The origin and chemical form of the sulfur species that contributes sulfide to the nascent BolA2--\[2Fe--2S\]--Glrx3 complex is not known, but could be initially coordinated by either BolA2, Glrx3, or both. An alternative model posits that the PCBP1--Fe--GSH--BolA2 complex could serve to repair or restore a damaged or partially assembled cluster on Glrx3; these models are not mutually exclusive and both could be occurring in cells.

The Glrx3--\[2Fe--2S\]~2~--BolA2~2~ complex can function as an Fe--S cluster chaperone, binding and transferring its \[2Fe--2S\] clusters to the apo- form of Ciapin1 (also called anamorsin). Ciapin1 coordinates a pair of Fe--S clusters and functions in the early steps of cytosolic \[Fe--S\] assembly^[@R29],[@R46]^. Cluster transfer from Glrx3--\[2Fe--2S\]~2~--BolA2~2~ to Ciapin1 has been observed *in vitro* and in cells. We show that PCBP1 provides an entry point for iron in the assembly or repair of cytosolic Fe--S clusters and that the PCBP1--Fe--GSH--BolA2 complex serves as an intermediate for the transfer of iron to Glrx3--BolA2. Whether the PCBP1--Fe--GSH--BolA2 complex can transfer iron to other targets or is required for the efficient capture of iron from other sources is an important question that awaits further investigation.

Online Methods {#S10}
==============

Plasmids {#S11}
--------

Plasmids pcDNA5-PCBP1 and pcDNA5-Flag-PCBP1 were created by amplifying PCBP1 from pYES2-Flag-PCBP1^13^ and subcloning the resulting fragment into pcDNA5/FRT/TO vectors (Thermo Fisher Scientific) containing 2xFlag at N-terminus using Gibson Assembly (New England Biolabs). Plasmids pcDNA5-BolA2, pcDNA5-BolA2-Flag, and pcDNA3--6x-myc-Glrx3 were obtained as mentioned previously^[@R27]^. Plasmids for expression of individual K-Homology domains of PCBP1 were created by deleting the different regions from pcDNA5-Flag-PCBP1: KH1 (Δ301--1089), KH2 (Δ85--309, Δ537--1089), KH3 (Δ85--879), KH1--2 (Δ559--1089), KH2--3 (Δ85--309), and ΔVr (Δ568--861) using Q5 Site-Directed Mutagenesis kit (New England Biolabs). Single substitution variants of PCBP1, KH3 and BolA2 were introduced into pcDNA5-Flag-PCBP1: C293S or into pcDNA5-Flag-KH3: C293S, G296A, R297A, G299A, N301A, E304S, R306A, R325A, S332A, R346A, E350A, C355S, N301A/R346A or into pcDNA5-BolA2-Flag: C31S, H68A using Q5 Site-Directed Mutagenesis kit (New England Biolabs). All plasmids were confirmed by DNA sequencing.

Cell Culture and Stable Cell Lines {#S12}
----------------------------------

HEK293 cells were grown in DMEM supplemented with 10% FBS, 50 U/ml penicillin G, and 50 μg/ml streptomycin. Flp-In T-Rex 293 cell lines (Thermo Fisher Scientific) containing stably integrated pcDNA5/FRT/TO vectors were constructed according to the manufacturer's instructions using pcDNA5-Flag-PCBP1 or pcDNA5-BolA2-Flag and maintained in DMEM supplemented with 10% tetracycline-free FBS (HyClone serum), 50 μg/ml hygromycin, and 15 μg/ml blasticidin. Where indicated, doxycycline was used at 1 μg/ml or iron was used as ferric ammonium citrate.

Protein Depletion by siRNA {#S13}
--------------------------

Cells were treated with 5--20 nM of the targeting Stealth siRNA ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) according to manufacturer's protocol. Non-targeting, scrambled sequence pools of siRNA were used as a control. Unless otherwise stated, cells were treated with 2 sequential siRNA treatments spaced by 24 hours using Lipofectamine RNAiMax transfection reagent (Invitrogen) and harvested 4 days after the initial transfection.

Co-immunoprecipitations and Immunoblotting {#S14}
------------------------------------------

HEK293 cell were transfected with 5--10 μg indicated plasmids using Lipofectamine 2000 transfection reagent (Invitrogen) and harvested 24 h post transfection. Stable cell line expressing indicated Flag epitope-tagged proteins were treated with 1 μg/ml doxycycline to induce expression of the respective gene for 24 h. Cells were lysed in IP buffer (100 mM Tris-HCl pH7.5, 40 mM KCl, 0.1% Nonidet P40, 5% glycerol, 5 mM GSH, 1x protease inhibitor cocktail, Roche), and clarified whole cell extracts were subjected to immunoprecipitation using anti-Flag agarose for 30 minutes at 4°C. Following 4 washes with IP buffer, immune complexes were eluted in 2X LDS sample buffer (Invitrogen) containing 10% β-mercaptoethanol at 95 °C for 10 min and analyzed by immunoblotting. Membranes were incubated with the indicated primary antibodies, followed by detection using IR dye-conjugated secondary antibodies (1:10,000, Li-Cor). Antibodies used for Western blotting were rat anti-Flag (1:2,000, BioLegend), chicken anti-PCBP1 (1:10,000)^[@R11]^, chicken anti-BolA2 (1:2,000)^[@R27]^, rabbit anti-Glrx3 (1:10,000), and rabbit anti-Nfs1 (1:1,000)^[@R47]^. Detection and quantitative analysis were performed using Odyssey CLx (Li-Cor) software. For quantification ratio of target protein to anti-Flag protein were calculated and normalized to control. Where indicated, glutathione was removed from IP buffer or iron was used at 10--100 μM as ferrous ammonium sulfate or iron chelators were used at 100 μM as a mixture of desferrioxamine B (Dfo)/ bathophenanthrolinedisulfonic acid (BPS).

Mass spectrometry analysis {#S15}
--------------------------

HEK293 cell lines expressing Flag-PCBP1 or the empty vector were grown in medium supplemented with 1 μg/ml doxycycline and 100 μM ferric ammonium citrate or 100 μM desferrioxamine B. Six 15-cm plates were harvested, and Flag immunoprecipitates were prepared as described previously^[@R48]^. High-salt washes were performed by increasing sodium chloride in the wash buffer to 500 μM. Immune complexes were eluted with Flag peptide, and the eluates were precipitated in 10% cold trichloroacetic acid. The precipitated eluates underwent tryptic digestion and mass spectrometry analysis as described previously^[@R48],[@R49]^. Proteomics dataset is available at MassIVE Repository (<https://massive.ucsd.edu/>) using the MSV000083887 accession.

^55^Fe or ^35^S-GSH labeling {#S16}
----------------------------

HEK293 cells were transfected with indicated plasmids or treated with 1 μg/mL doxycycline and 2--5 μM ^55^FeCl~3~ (PerkinElmer) for 16 h. Cells were washed three times with PBS, including first wash with PBS + 10 mM EDTA, 2 mM BPS, and 50 μM Sodium ascorbate. Whole cell extracts were prepared using IP buffer. Immunoprecipitation was then performed using anti-Flag agarose for 30 min at 4°C with gentle tumbling. Immune complexes were washed 4 times with IP buffer and retained ^55^Fe was quantitated by liquid scintillation counting (LSC500, Beckman Coulter). IPs from cells transfected with control plasmid or not treated with doxycycline were used to determine nonspecific ^55^Fe background. Co-precipitating ^55^Fe was normalized to total cellular ^55^Fe accumulation and Flag-tag protein level in whole cell extracts or IP fractions.

For ^35^S-glutathione (^35^S-GSH) labelling, whole cell extracts were prepared from cells expressing FLAG-tagged proteins and captured on anti-FLAG resin. Immobilized FLAG-tagged proteins were labelled with 100 μM ^35^S-GSH (\~1 μCi, PerkinElmer) and incubated for 20 min at 4°C with gentle tumbling. Beads were washed 1 time with IP buffer containing 100 μM GSH and retained ^35^S-GSH was quantitated by liquid scintillation counting (LSC500, Beckman Coulter). Bound ^35^S-GSH was normalized to unbound ^35^S-GSH and Flag-tag protein level in whole cell extracts or IP fractions.

Protein Expression and Purification {#S17}
-----------------------------------

K-homology domain (KH3-Flag) of human PCBP1 was amplified from pcDNA5-KH3-Flag, cloned into a pCDF-6xHis-SUMO fusion construct vector and transformed into BL21star(DE3)pLysS *Escherichia coli* (Invitrogen) competent cells containing ampicillin resistance. Competent cells were grown in 1L LB media at 37°C to an OD~600~ of 0.6, induced with 1 mM IPTG and grown for 4 h at 37°C. Cells were collected, resuspended in 20 ml of buffer B (100 mM Tris pH 7.5, 150 mM NaCl, 5 mM GSH, 40 mM imidazole, 10% glycerol, and 1 mM tris-2-carboxyethyl-phosphine (TCEP)), containing 25 U/ml Benzonase nucleases (Sigma) and EDTA-free protease inhibitor cocktail (Roche). Cells were lysed with a multi shot constant system (Pressure Bioscience). The extract was spin down at 25,000 rpm for 30 min and loaded onto an AKTA HisTrap HP nickel column (GE Healthcare). Separation was carried out using a linear gradient starting with buffer B and ending with buffer E (100 mM Tris pH 7.5, 150 mM NaCl, 5 mM GSH, 400 mM imidazole, 10% glycerol, 1 mM TCEP). Protein eluted between 100 -- 250 mM imidazole. The 6xHis-SUMO tag was cleaved by adding SUMO protease (Invitrogen) according to the manufacturer's instructions. Protein was buffer-exchanged with buffer B using Ultra-3 Centricon (Millipore) filtration devices and pass through the nickel column again to separate the tag from the untagged protein. Protein purity was analyzed by 4--12% SDS-PAGE followed by Coomassie Brilliant Blue staining and Western blot using an anti-Flag antibody.

Human BolA2-Strep tagged construct was generated by inserting Strep-tag II sequence at C-terminal in pETDuet-1-BolA2^Δ1−66^ (gift from Caryn Outten). pETDuet-1-BolA2^Δ1--66^-Strep plasmid was transformed into BL21star(DE3)pLysS *E. coli* (Invitrogen) competent cells. Competent cells were grown in 1 L of LB medium at 30 °C until the OD~600~ reached 0.6 and induce with 1 mM IPTG for 18 h. Strep-Tactin purification was performed according to manufacturer's protocol. Briefly, cells were resuspended in 20 mL buffer W (100 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 10% glycerol, and 1 mM TCEP) and lysed with a multi shot constant system. The extract was spin down at 25,000 rpm for 30 min and loaded onto gravity flow Strep-Tactin Superflow high capacity column (IBA). Protein were eluted with buffer D (100 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM Desthiobiotin, 10% glycerol, and 1 mM TCEP). Buffer exchange was completed using Ultra-3 Centricon (Millipore) filtration devices. Protein purity was analyzed by 4--12% SDS-PAGE followed by Coomassie Brilliant Blue staining and Western blot using an anti-BolA2 antibody.

*In vitro* Reconstitution {#S18}
-------------------------

Purified KH3-Flag and BolA2-Strep (0.1 -- 4 μM) were mixed in 200 μL IP buffer (100 mM Tris-HCl pH7.5, 40 mM KCl, 0.1% Nonidet P40, 5% glycerol, 1 mM TCEP), containing 100 μM ferrous ammonium sulfate, Fe-Chelator (100 μM Desferoxamine, 100 μM BPS), or glutathione (0 -- 5 mM) as indicated. The *in vitro* mix were incubated with anti-Flag agarose for 20 minutes at 4°C with gentle tumbling. Beads were washed 3 times with IP buffer to remove uncaptured proteins before eluting with 2X LDS sample buffer (Invitrogen) containing 10% β-mercaptoethanol at 95 °C for 10 min. The input and elute samples were subjected to immunoblot analysis and quantitation.

For ^35^S-GSH labelling of KH3-Flag, purified 5 μM KH3-Flag was labelled with 100 μM ^35^S-GSH (\~1 μCi, PerkinElmer) in IP buffer and incubated with anti-FLAG resin for 20 min at 4°C. Beads were washed 1 time with IP buffer containing 100 μM GSH and retained ^35^S-GSH was quantitated by liquid scintillation counting (LSC500, Beckman Coulter). Bound ^35^S-GSH was normalized to unbound ^35^S-GSH and KH3-Flag protein levels, and *in vitro* mix without KH3-Flag was used as a control.

Size Exclusion Chromatography (SEC) {#S19}
-----------------------------------

SEC was performed on HiPrep 16/60 Sephacryl S-100 high resolution column using AKTA purifier system with simultaneous UV/vis detection (GE Healthcare). The column was calibrated using the bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), cytochrome c oxidase (12 kDa), and aprotinin (6 kDa) with the SEC buffer (100 mM Tris, pH 7.5, 40 mM KCl, and 1 mM TCEP). Purified KH3-Flag and BolA2-Strep (50 μM) were mixed in presence of 100 μM ferrous ammonium sulfate and 1 mM glutathione or 500 μM ammonium sulfate, and analyzed by SEC on column pre-equilibrated with the SEC buffer. The elution profiles were followed by absorption at 280 nm and protein identities in elution fractions were checked with SDS-PAGE and Western blotting.

Microscale Thermophoresis (MST) {#S20}
-------------------------------

Purified His-SUMO-KH3 domain was washed with buffer containing 100 mM Tris pH 7.5, 300 mM NaCl, 5 mM ammonium sulfate, 10% glycerol, 1 mM TCEP to avoid the intramolecular interactions and remove nucleic acid contamination. His-SUMO-KH3 domain were fluorescently labeled using the Monolith His-Tag Labeling Kit RED-tris-NTA 2nd Generation as recommended by the supplier (NanoTemper Technologies, Germany). The fluorescently labelled protein (200 nM) was titrated with serial dilutions of glutathione (from 5 mM to 0.1 μM), in presence or absence of 10 μM FeSO~4~, in buffer containing 50 mM Tris, pH 7.5, 40 mM KCl, 0.2 mM TCEP, and 0.05% Tween20. Thermophoresis assays were performed using Monolith NT.115 at 25°C (LED power 60%, IR laser power 40%) in premium coated capillaries. Three independent experiments were recorded at 680 nm. The thermophoresis data were processed by MO Affinity Analysis (NanoTemper) and Prism7 (GraphPad) software to estimate the K~D~ values.

Iron binding affinity {#S21}
---------------------

Iron binding affinities were determined using ratiometric metal indicator mag-fura-2 (MF2) and fura-4F (Invitrogen) as described previously^[@R37],[@R38]^. Both MF2 and fura-4F forms a 1:1 complex with most divalent cations. The apo indicator has an absorbance maximum at 366 nm (MF2) or 380 nm (fura-4F) which shifts toward 325 nm concurrent with metal binding. For determination of metal binding affinity to protein, we tracked the absorbance decrement of the MF2 or fura-4F, in presence of protein, upon addition of metal ion. KH3-Flag protein (10 μM) and indicator (10 μM) were titrated with 1 mM FeSO~4~ in Chelex treated buffer 50 mM HEPES (pH 7.3), 150 mM NaCl, 1 mM TCEP, with or without 5 mM GSH. Concentrations of free indicator was determined using extinction coefficients for MF2 (ε~366~ 29,900 M^−1^ cm^−1^) and fura-4F (ε~380~ 21,000 M^−1^ cm^−1^). The variable Q and P are solved for using [equations 1](#FD1){ref-type="disp-formula"} and [2](#FD2){ref-type="disp-formula"} respectively. $$\text{Q} = \left( {\varepsilon - \varepsilon_{\text{L}}} \right)/\left( {\varepsilon_{\text{I}} - \varepsilon} \right)$$ $$\text{P} = \text{M}_{\text{t}} - \left\lbrack {\left( {1/\text{QK}_{a}} \right) - \left( {\text{F}_{t}/\text{Q} + 1} \right)} \right\rbrack$$ Q is equal to the ratio of free to metal-bound indicator, ε, ε~I~, and ε~L~ are the observed, free indicator, and metal-bound indicator extinction coefficients respectively. P is the concentration of protein-metal complex, M~t~ is the total metal concentration, K~a~ is the association constant for the metal-indicator complex, and F~t~ is the total indicator concentration. Ratio of metal-bound KH3 to total KH3 was plotted as a function of free iron concentration and the data was fitted by Michaelis-Menten analysis to obtain the dissociation constant (K~D~) and stoichiometry (N). Reported errors for K~D~ and stoichiometry are asymptotic standard errors provided by the Prism7 (GraphPad).

Statistics {#S22}
----------

Standard deviation (SD) and standard error of the mean (SEM) were calculated, and statistical significance was determined by two-tailed unpaired *t*-test or one-way ANOVA analysis using Prism7 (GraphPad) software.

Data Availability {#S23}
-----------------

The proteomics dataset ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) is available at MassIVE Repository (<https://massive.ucsd.edu/>) with the accession number MSV000083887.
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![BolA2 forms a complex with PCBP1 and binds in absence of Glrx3.\
**a,b,** Binding between PCBP1 and BolA2 in cells. HEK293 cells were transfected with plasmid (p) negative control (−), PCBP1-Flag (PCBP1-F; **a**), or BolA2-Flag (BolA2-F; **b**) and anti-Flag immunoprecipitation (IP) performed. Whole cell extracts (WCE) and immune complexes were analyzed by immunoblot using antibodies for PCBP1, BolA2, and Flag-tag. **c,** Binding of endogenous PCBP1 with BolA2 in cells. Tetracycline-inducible stable cell lines expressing empty vector (EV) or BolA2-Flag (BolA2-F) were treated overnight with doxycycline, transfected with control (−) or PCBP1 plasmid, and analyzed as in **b**. **d,** Glrx3-independent formation of PCBP1--BolA2 complex in cells. BolA2-F or EV cell lines were transfected with non-targeting (NT) or Glrx3 siRNA and analyzed as in **b**. **e,** Glrx3 competes with PCBP1 for interaction with BolA2 in cells. HEK293 cells were transfected with control (Con), *myc*-Glrx3 (m-Glrx3), or BolA2-F plasmids and analyzed as in **b**. In **d** and **e**, WCE and immune complexes were analyzed by immunoblot using antibodies for PCBP1, BolA2 or Glrx3 and the relative ratio of co-precipitated PCBP1 to BolA2-F in IP was quantified (*right*). All experiments were repeated independently three times with similar results. Bar graphs represent means ± SD. Significant *P* values (*P* \< 0.05), as determined by two-tailed unpaired *t*-test relative to control, are shown. Uncropped western blots are presented in [Supplementary Figure 13](#SD1){ref-type="supplementary-material"}.](nihms-1532983-f0001){#F1}

![BolA2 requires PCBP1, but not Glrx3, to form an iron-binding complex.\
**a,** Isolation of ^55^Fe-containing BolA2 complexes from cells. BolA2-F and EV inducible cell lines were labeled with ^55^FeCl~3~ for 16 h. WCE and anti-Flag immune complexes were analyzed by scintillation counting (*left*) and immunoblot (*right*). Non-specific (EV) and specific (BolA2-F) ^55^Fe-binding was normalized to whole cell ^55^Fe content and expressed relative to EV control. Data are means ± SD of *n* = 5 independent experiments. **b,** ^55^Fe binding to BolA2 complexes from cells lacking Glrx3. Inducible BolA2-F cells were treated with NT or Glrx3 siRNA and labeled with ^55^FeCl~3~. WCE and anti-Flag IPs were analyzed by scintillation counting and immunoblotting for Glrx3 and BolA2-F. Quantification (*left*) of specifically bound ^55^Fe (red bars) and ratio of co-precipitated Glrx3 to IP BolA2-F (grey bars) are normalized to NT control. Data are means ± SD of *n* = 3 independent experiments. **c,** PCBP1-dependent ^55^Fe binding to BolA2 complexes. Inducible BolA2-F cells were treated with non-targeting (−), Glrx3, or PCBP1 siRNAs and transfected with control (−) or PCBP1 plasmids. Cells were labeled with ^55^FeCl~3~, WCE and immune complexes were analyzed by scintillation counting for ^55^Fe (*left*) and immunoblotting for Glrx3, PCBP1 and BolA2-F (*right*). Specifically bound ^55^Fe was normalized to IP BolA2-F and expressed relative to NT control. Data are means ± SD of *n* = 3 independent experiments. For all experiments significant *P* values (*P* \< 0.05), as determined by two-tailed unpaired *t*-test relative to control, are shown. Uncropped western blots are presented in [Supplementary Figure 14](#SD1){ref-type="supplementary-material"}.](nihms-1532983-f0002){#F2}

![Stabilization of PCBP1--BolA2 complex by iron and glutathione without inorganic sulfur.\
**a,** Requirement of iron and glutathione for PCBP1--BolA2 complex stabilization. HEK293 cells were transfected with the indicated plasmids, then lysed in IP buffer +/− 5 mM glutathione (GSH) or 100 μM chelator mix (Dfo/Bps). WCE and anti-Flag IPs were analyzed by immunoblot using antibodies for PCBP1 and BolA2 (*left*) with quantitation (*right*). Data are means ± SD of *n* = 3 independent experiments. Significant *P* values (*P* \< 0.05), as determined by two-tailed unpaired *t*-test relative to +GSH control, are shown. **b,** ^55^Fe bound to BolA2 complexes from cells lacking Nfs1. Inducible EV or BolA2-F cells were treated with NT, Glrx3, or Nfs1 siRNAs and labeled with ^55^FeCl~3~. WCE and anti-Flag IPs were analyzed by immunoblotting for Nfs1, Glrx3, PCBP1 and BolA2-F and by scintillation counting (*left*) with quantitation (*right*). Data are means ± SD of *n* = 3 independent experiments. **c,** Requirement of BolA2 iron-binding residues for interactions with Glrx3 and PCBP1. Stable cell lines expressing EV, wild type (WT), C31S or H68A mutants of BolA2-F were examined by IP (*left*) with quantitation (*middle*). Data are means ± SD of *n* = 3 independent experiments. Significant *P* values (*P* \< 0.01), as determined by two-tailed unpaired *t*-test relative to WT control, are shown. Homology model of human BolA2 on murine structure (PDB: 1V9J, sequence identity 87%), conserved iron binding residues shown in red (*right*). Uncropped western blots are presented in [Supplementary Figure 15](#SD1){ref-type="supplementary-material"}.](nihms-1532983-f0003){#F3}

![Requirement of PCBP1 in delivery of iron to Grx3--\[2Fe--2S\]--BolA2 complex.\
**a,** Requirement of GSH for iron binding to PCBP1. HEK293 cells were transfected with control, BolA2, or PCBP1-F plasmids and labelled with ^55^FeCl~3~. Anti-Flag IPs were performed +/− 5 mM GSH. WCE and anti-Flag IPs were analyzed by immunoblotting for BolA2 and PCBP1-F (*left*) and by scintillation counting for ^55^Fe quantitation (*right*). Data are means ± SD of *n* = 3 independent experiments. **b,** Loss of Glrx3--BolA2 complexes in cells lacking PCBP1. Inducible BolA2-F cells were treated with NT, PCBP1, or PCBP2 siRNA and analyzed by IP and immunoblotting for Glrx3 and BolA2 (*left*) with quantitation (*right*). Data are means ± SD of *n* = 6 independent experiments. **c,** Restoration of Glrx3--BolA2 complexes by iron supplementation in cells lacking PCBP1. Inducible BolA2-F cells were transfected with NT or PCBP1 siRNA and treated overnight with 50 μM FeCl~3~. WCE and anti-Flag IPs were analyzed by immunoblotting against Glrx3 and BolA2 (*left*) with quantitation (*right*). Data are means ± SD of *n* = 3 independent experiments. For all experiments significant *P* values (*P* \< 0.05), as determined by two-tailed unpaired *t*-test relative to control, are shown. Uncropped western blots are presented in [Supplementary Figure 16](#SD1){ref-type="supplementary-material"}.](nihms-1532983-f0004){#F4}

![KH3 domain of PCBP1 binds BolA2 and restores BolA2--Glrx3 complex formation.\
**a,** Iron- and glutathione-dependent interaction of BolA2 with KH1 and KH3 of PCBP1. HEK293 cells were transfected with plasmids for Flag-tagged, full length PCBP1 (P1~FL~) or individual KH domains (KH1, KH2, and KH3). Anti-Flag IP was performed in IP buffer +/− GSH and Dfo/Bps. IPs were analyzed by immunoblotting for BolA2 and Flag (*left*). Ratios of co-precipitated BolA2 to each KH-F is normalized to full length PCBP1 (*right*). Data are means ± SD of *n* = 3 independent experiments. Statistical significance level was calculated by one-way ANOVA analysis (*F* = 39.05, d.f. = 29, *P* \< 0.0001) with a Dunnett's multiple comparison test, \**P* ≤ 0.0001 compared to P1~FL~+GSH. **b,** Requirement of KH3 domain to form Glrx3--BolA2 complex. Inducible BolA2-F cells were treated with NT or PCBP1 siRNA, then transfected with siRNA-resistant plasmids as indicated. WCE and anti-Flag IPs were analyzed by immunoblotting against Glrx3, PCBP1 and Flag (*left*) with quantitation (*right*). Data are means ± SD of *n* = 4 independent experiments. Significant *P* values (*P* \< 0.05), as determined by two-tailed unpaired *t*-test, are shown. **c,** Distinct iron and GSH binding sites on KH3 domain required for BolA2 interaction. Cells expressing BolA2 and KH3-Flag variants, as indicated, were labeled with ^55^FeCl~3~. Anti-Flag IPs were directly analyzed for BolA2 (see [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}) or ^55^Fe binding. Alternatively, washed complexes were incubated with 100 μM ^35^S-GSH and analyzed for GSH binding. Ratio of co-precipitated BolA2 or ^55^Fe or ^35^S-GSH to each KH3-F variant is normalized to WT. Data are means ± SD of *n* = 3 independent experiments. Statistical significance level was calculated by one-way ANOVA analysis (*F* = 43.91, d.f. = 20, *P* \< 0.0001) with a Dunnett's multiple comparison test, \**P* ≤ 0.0001 compared to WT. **d,** Ribbon structure of KH3 domain (PDB: 1WVN) illustrating ligands for GSH binding (blue sticks) and iron binding (red sticks). **e,** Requirement of Cys293 residue on PCBP1 to form Glrx3--BolA2 complex. Inducible BolA2-F cells were treated with NT or PCBP1 siRNA, then transfected with siRNA-resistant plasmids as indicated. WCE and anti-Flag IPs were analyzed by immonoblot against Glrx3, PCBP1 and Flag (*left*) with quantitation (*right*). Data are means ± SD of *n* = 3 independent experiments. Significant *P* values (*P* \< 0.05), as determined by two-tailed unpaired *t*-test, are shown. Uncropped western blots are presented in [Supplementary Figure 17](#SD1){ref-type="supplementary-material"}.](nihms-1532983-f0005){#F5}

![Reconstitution of KH3--BolA2 complex with iron and GSH *in vitro*.\
**a,** GSH binding affinity for KH3 domain increased by iron. Purified, fluorescently labeled KH3 domain (200 nM) was mixed with increasing concentrations of GSH, without added iron (green) or with 10 μM FeSO~4~ (orange) and apparent dissociation constants (K~D~) were determined for GSH using microscale thermophoresis. Data are means ± SEM of *n* = 4 independent experiments. **b,** Increased Fe(II) binding affinities of WT and C293S KH3 in presence of GSH. Dissociation constants (K~D~) of WT (red) and C293S (blue) KH3 for Fe(II) were determined using Mag-fura-2 competition, +/− 5 mM GSH. Data are means ± SD of *n* = 4 independent experiments. **c,d,** Requirement of iron and glutathione for reconstitution of KH3--BolA2 complex *in vitro*. Recombinant, purified BolA2-Strep (BolA2-S, 1 μM) and WT (**c**) or C293S KH3-Flag (KH3-F, 1 μM; **d**) were mixed in IP buffer +/− 5 mM GSH or 100 μM FeSO~4~ and anti-Flag IP was performed. IP input and immune complexes were analyzed by immunoblot against BolA2 and Flag-tag. Blots are representative of *n* = 3 independent experiments with similar results. **e,** GSH-dependent binding of KH3 to BolA2 *in vitro*. Purified BolA2-S and KH3-F were mixed in IP buffer containing 100 μM FeSO~4~ with the indicated concentrations of GSH and analyzed by anti-Flag IP and immunoblotting. Ratio of BolA2 to IP KH3-F was plotted as a function of GSH concentration and the data was fitted by Michaelis-Menten analysis to obtain the K~D~. Data are means ± SD of *n* = 3 independent experiments. **f,** Apparent binding affinity of BolA2 to KH3 domain. Purified KH3-F (4 μM) was mixed with indicated concentrations of BolA2-S (4--0.1 μM) in IP buffer containing 5 mM GSH and 100 μM FeSO~4.~ Anti-Flag IP and Western blotting was performed. Ratio of bound to unbound BolA2 was plotted as a function of total BolA2 concentration and the data was fitted by Michaelis-Menten analysis to obtain the K~D~. Data are means ± SD of *n* = 3 independent experiments. Uncropped western blots are presented in [Supplementary Figure 18](#SD1){ref-type="supplementary-material"}.](nihms-1532983-f0006){#F6}
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